Caris Life Sciences, Inc. (CAI) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Current Price
$19.86
Price Target
$31.33
Target Range
$26.00 — $38.00
Analyst Rating
Buy
Forward P/E62.1x
Trailing P/E-6.2x
Forward PEG—
Implied Growth+199.5%
Median Target$30.00
Analyst Spread38.3%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$26
+30.9%
Consensus
$31
+57.8%
Bull Case
$38
+91.3%
CAI Price Target Analysis
Updated March 5, 2026As of March 5, 2026, Caris Life Sciences, Inc. (CAI) has a Wall Street consensus price target of $31.33, based on estimates from 6 covering analysts. With the stock currently trading at $19.86, this represents a potential upside of +57.8%. The company has a market capitalization of $33.21B.
Analyst price targets range from a low of $26.00 to a high of $38.00, representing a 38% spread in expectations. The median target of $30.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CAI trades at a trailing P/E of -6.2x and forward P/E of 62.1x. Analysts expect EPS to grow +199.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+40.9%
Avg Forward P/E42.0x
Peers with Coverage5 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
| CAICaris Life Sciences, Inc. | $33.2B | $19.86 | $31.33 | +57.8% | Buy | 62.1x | 6 |
 VCYTVeracyte, Inc. | $2.9B | $36.27 | $47.25 | +30.3% | Buy | 22.0x | 20 |
 ADPTAdaptive Biotechnologies Corporation | $2.5B | $16.44 | $21.25 | +29.3% | Buy | — | 17 |
 NAUTNautilus Biotechnology, Inc. | $331M | $2.62 | $2.50 | -4.6% | Buy | — | 5 |
 CDIOCardio Diagnostics Holdings, Inc. | $141M | $5.26 | — | — | — | — | — |
 SEERSeer, Inc. | $103M | $1.85 | — | — | Hold | — | 4 |
 IMDXInsight Molecular Diagnostics Inc. | $95M | $5.47 | $10.50 | +92.0% | Buy | — | 11 |
 ASBPAspire Biopharma Holdings, Inc. | $63M | $1.32 | — | — | — | — | — |
 YDESYD Bio Limited Ordinary Shares | $35M | $8.45 | — | — | — | — | — |
 AIMDAinos, Inc. | $7M | $1.51 | — | — | — | — | — |
Upside Potential Comparison
IMDXCAIVCYTADPTNAUTSee CAI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CAI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CAI vs LLY
See how CAI stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
What is the CAI stock price target for 2026?
The consensus Wall Street price target for CAI is $31.33, representing 57.8% upside from the current price of $19.86. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is CAI a buy, sell, or hold?
CAI has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $31.33 implies 57.8% upside from current levels.
Is CAI stock overvalued or undervalued?
At a forward P/E of 62.0625x, CAI trades at a premium valuation. The consensus price target of $31.33 (57.8% upside) suggests analysts still see growth justifying the multiple.
How high can CAI stock go?
The most bullish Wall Street analyst has a price target of $38 for CAI, while the most conservative target is $26. The consensus of $31.33 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover CAI stock?
CAI is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the CAI stock forecast?
The 12-month CAI stock forecast based on 6 Wall Street analysts shows a consensus price target of $31.33, with estimates ranging from $26 (bear case) to $38 (bull case). The median consensus rating is "Buy".
What is CAI's forward P/E ratio?
CAI trades at a forward P/E ratio of 62.1x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy CAI stock?
Wall Street analysts are very optimistic on CAI, with a "Buy" consensus rating and $31.33 price target (57.8% upside). 5 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do CAI price targets vary so much?
CAI analyst price targets range from $26 to $38, a 38% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $31.33 consensus represents the middle ground.